Australia's Island Pharmaceuticals hits nearly 1-month high on ethics approval

Island Pharmaceuticals

07/11/2023 03:29

** Shares of Australia's Island Pharmaceuticals  ILA.AX 
rise as much as ~9.6% to A$0.08, marking its biggest intraday
pct gain since Sept. 27
    ** Stock at its highest level since Oct. 12
    ** The biotechnology co says granted human research ethics
approval to commence its ISLA-101 Single Ascending Dose study 
    ** ISLA-101, a drug candidate being repurposed for
prevention and treatment of dengue and other mosquito (or
vector) borne diseases - ILA
    ** Adds study to be performed at Scientia Clinical
Research’s trial facilities in Sydney, Australia 
    ** Says patient screening and dosing to commence
immediately, with final read-out in early 2024
    ** Stock down 60.5% YTD, as of last close

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com;))